Twenty women had primary amenorrhoea. Gonadal dysgenesis confirmed by gynaecography or laparoscopy was present in five of these, two of whom showed chromosomal abnormalities. Laparoscopy in seven of the remaining 15 patients showed small ovaries but biopsy showed plentiful follicular tissue in five women.
Of the other 36 amenorrhoeic patients six presented with menopausal symptoms suggesting premature ovarian failure; no follicles were seen in ovarian biopsies from four, and in the other two, though occasional follicles were observed, there was no change in urinary oestrogen levels after large doses of human menopausal gonadotrophins. Amenorrhoea occurred after stopping oral contraception in seven women, after a miscarriage in one, and after delivery in one. test; there was no increase in pregnanediol excretion and no menstruation (see table) . Women with Secondary Amenorrhoea.-Two women showed the "normal ovulatory pattern" after clomiphene accompanied by a rise in pregnanediol excretion ( fig. 4) and menstruated after the course. Four patients showed a similar early rise of LH, but LH levels then fell with no evidence of a secondary peak and no rise in pregnanediol. Four women showed no early rise in LH and levels remained low throughout the test. The two patients with suspected premature ovarian failure had raised basal LH levels unaffected by clomiphene (see table) .
Women with Anovulatory Cycles.-All five women showed an early LH rise on clomiphene treatment (see table) . There was a subsequent rise to a peak in one case, a secondary rise though no clear LH peak in three, and a slow decline in LH levels after the early rise with no subsequent peak in one. Significant rises in urinary pregnanediol were observed in each case. The clomiphene stimulation test presents certain practical difficulties: the preovulatory LH peak, for example, may be missed unless daily blood samples are taken. In our study, however, all patients with an early LH rise during clomiphene administration also showed a normal LH and FSH response to LH/FSH-RH. This rise usually started on the second or third day, reached a maximum between the seventh and 11th days, and could be monitored every two or three days. For clinical purposes we therefore suggest sampling on days, 1, 3, 5, 8, and 11 of clomiphene administration, an LH rise of at least 3-5 U/I to a maximum above 6 U/I over this period indicating the integrity of the hypothalamo-pituitary-ovarian axis. Pregnanediol or other indirect indices of ovulation may be monitored also, but this is not essential.
The LH/FSH-RH test is thus useful in cases of suspected anovulation. An absent or impaired response implies an abnormality, primary or secondary, of the pituitary gonadotrophs, and if the situation is irreversible in such cases infertility may be treated with gonadotrophins provided there is biopsy evidence of adequate follicular tissue."°With a normal or exaggerated LH-RH response it is important to carry out a clomiphene stimulation test also. In women with primary ovarian failure the exaggerated response to LH/FSH-RH is confirmed by high LH levels unaffected by clomiphene. Patients with normal LH/FSH-RH responses may be divided into those with disturbed cyclical gonadotrophin release, who respond to clomiphene, and those with a block in releasing-hormone production, who do not. Infertility in the former group may respond to repeated courses of clomiphene, with or without human chorionic gonadotrophin to induce follicular rupture. In the latter group LH/FSH-RH itself may eventually prove to be an effective and physiological alternative to gonadotrophin therapy.
